Home » GlaxoSmithKline, Genmab Get Conditional Approval for Arzerra in EU
GlaxoSmithKline, Genmab Get Conditional Approval for Arzerra in EU
GlaxoSmithKline and Denmark’s Genmab A/S said that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP
gave a positive opinion for conditional approval for its Arzerra, a treatment for refractory chronic lymphocytic leukaemia.
RTTNews
RTTNews
Upcoming Events
-
07May
-
14May
-
30May